Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer
Conditions: Refractory Metastatic Gastric Cancer

Interventions: Drug: TAS-102; Drug: Placebo

Sponsors: Taiho Oncology, Inc.

Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 28, 2024Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments